Guidelines for the treatment of skin and mucosal lesions in Behçet's disease: A secondary publication

Nakamura, Koichiro; Iwata, Y.; Asai, Jun; Kawakami, Tamihiro; Tsunemi, Yuichiro; Takeuchi, Masaki; Mizuki, Nobuhisa; Kaneko, Fumio

doi:10.1111/1346-8138.15207

Cited by 22 publications

(18 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Otras alternativas de tratamiento que se han prescrito en pacientes con EB grave, algunos de ellos fuera de ficha técnica, son anakinra (1-4 mg/kg/día), canakinumab (dosis ajustada según el peso del paciente a 4-8 mg/kg cada 4-8 semanas), tocilizumab (dosis ajustada según el peso del paciente a <30 kg: 10 mg/kg, >30 kg: 8 mg/kg cada 4 semanas). Otras alternativas son ustekinumab, secukinumab, apremilast y micofenolato mofetilo, pero aún se precisa mayor evidencia para establecer recomendaciones en la población pediátrica 9,10 .…”

Section: Discussionunclassified

Enfermedad de Behçet en pediatría. Experiencia en un hospital de tercer nivel

Giacaman¹,

Mir-Perello²,

Lpez-Garca³

et al. 2021

MCUT

View full text Add to dashboard Cite

Introducción: El diagnóstico de la enfermedad de Behçet (EB) es clínico y en los niños puede ser un desafío dadas la baja prevalencia y la aparición insidiosa de los síntomas, lo que lleva en la mayor parte de los casos a un retraso del diagnóstico. Objetivo: Describir las características clínicas de los pacientes menores de 16 años con sospecha de EB en seguimiento en un hospital de tercer nivel. Material y métodos: Se realizó un estudio descriptivo de corte transversal que incluyó a todos los pacientes bajo seguimiento por sospecha de

show abstract

Section: Discussionunclassified

Enfermedad de Behçet en pediatría. Experiencia en un hospital de tercer nivel

Giacaman¹,

Mir-Perello²,

Lpez-Garca³

et al. 2021

MCUT

View full text Add to dashboard Cite

show abstract

“…Although several approaches have been proposed for the treatment of BD patients, there is no consensus regarding a single management strategy being superior to others [22]. In a recent publication, Nakamura et al discussed the currently accepted diagnosis and management protocols for the mucocutaneous variant of BD in the Japanese population and recommended systemic colchicine therapy over systemic steroids for oral and genital ulcers [23]. In a randomized crossover trial, Davatchi et.…”

Section: Discussionmentioning

confidence: 99%

A Case of HLA-B51 Positive Mucocutaneous Variant of Behçet’s Disease in a Young Indian Male: A Case Report

Sen

Majumder²

2021

Int J Clin Res

View full text Add to dashboard Cite

Background: Behçet’s disease is a rare, systemic inflammatory disorder of unknown etiology affecting the mucocutaneous, vascular, skeletal, ophthalmic, gastrointestinal, and neurological systems. While the exact etiopathogenesis of Behçet’s disease is yet to be established, numerous studies have supported a strong possibility of underlying genetic factors. It is comparatively more common in Turkey, the Middle East, and Mediterranean regions, and only a few cases have been reported from the Indian subcontinent so far. Although several immunological and genetic associations have been suggested, the diagnosis of Behçet’s disease remains primarily clinical and of exclusion. Case Report: In this report, we describe the case of a 22-year-old Indian male who developed multiple aphthous ulcers over his tonsillar pillars and pharyngeal wall following an episode of acute tonsillopharyngitis. Over the course of the next few days, he reported the presence of a genital ulcer and papulopustular lesions over his chest, back and face, eventually prompting a diagnosis of Behçet’s disease. He was treated with oral colchicine and was found to be in remission during a six-week follow-up. Conclusion: This case emphasizes the importance of awareness regarding Behçet’s disease among clinicians in India and warrants further studies on the epidemiology, immunopathogenesis, and management protocols of Behçet’s disease, especially in this country for a better understanding of its prevalence, manifestations, and disease course.

show abstract

“…(I) Skin pathergy reaction is a pustule formation at the needle site after 24 h on the forearm. (A,F,H,I) are derived from Nakamura et al ( 3 , 4 ).…”

Section: Oral Ulcersmentioning

confidence: 99%

“…However, specific clinical types with vascular, gastrointestinal, and central nervous system involvement have also been reported (1)(2)(3)(4). Given the lack of definitive diagnostic laboratory and histopathological tests for the disease, diagnosis has solely been based on clinical findings.…”

Section: Introductionmentioning

confidence: 99%

Mucocutaneous Manifestations of Behçet's Disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic, relapsing, systemic inflammatory disease with clinical features showing mucocutaneous lesions involving the ocular, articular, and further miscellaneous organs. Mucocutaneous manifestations, one of the most characteristic signs of BD, have been most commonly observed upon onset or at any disease stage and are exceptionally important in its diagnosis. Given the lack of specific diagnostic laboratory tests for BD, diagnosis has been based on clinical findings. All diagnostic criteria published have thus far relied heavily on mucocutaneous manifestations, particularly oral ulcers (OU), genital ulcers (GU), cutaneous lesions, and pathergy test positivity. Worldwide, OU, GU, cutaneous lesions, and ocular and articular manifestations have been the most common symptoms, with erythema nodosum (EN)-like lesions and papulopustular lesions being the most prevalent cutaneous manifestations. While majority of the patients worldwide have reported OU as the most frequent symptom upon disease onset, GU, and EN-like lesions have also been identified upon onset. Considering that mucocutaneous symptoms precede severe organ involvement in most patients, familiarity with such symptoms is imperative for early diagnosis and prevention of potentially serious organ involvement through appropriate management.

show abstract

Guidelines for the treatment of skin and mucosal lesions in Behçet's disease: A secondary publication

Cited by 22 publications

References 33 publications

Enfermedad de Behçet en pediatría. Experiencia en un hospital de tercer nivel

Enfermedad de Behçet en pediatría. Experiencia en un hospital de tercer nivel

A Case of HLA-B51 Positive Mucocutaneous Variant of Behçet’s Disease in a Young Indian Male: A Case Report

Mucocutaneous Manifestations of Behçet's Disease

Contact Info

Product

Resources

About